Murali is a serial entrepreneur with over fifteen years of experience in drug discovery and startup venture creation who currently serves as the Founder at Educible Therapeutics. At Educible, his primary focus is on developing novel oral small molecules that can be combined with other mechanisms of action (such as GLP-1RA) to enhance weight loss effects and improve tolerability. Prior to his role at Educible, Murali held positions at Novartis and other venture-backed biotech companies, where he played a pivotal role in the target discovery, validation, and advancement of drug candidates across various therapeutic areas. Furthermore, he demonstrated his entrepreneurial spirit by founding a company, where he led teams in developing drugs that mimic the metabolic benefits associated with gastric bypass surgery.

 Murali’s academic credentials include a Ph.D. in molecular biology from Rutgers University, a post-doctoral fellowship at Harvard Medical School and a MBA from Cornell SC Johnson School of Management.